nextpoint therapeutics

The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. NextPoint's programs aim to deliver monotherapies for cancer patients without viable treatment options. & Medical Devices, Crop Menu, Our US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). a Glance, Latest status, Contact NextPoint Therapeutics Raises $80M in Series B Financing Jan 10, 2023| staff reporter Save for later NEW YORK - NextPoint Therapeutics said on Tuesday that it has raised $80 million in Series B financing, which it will put toward advancing its precision oncology drugs targeting the HHLA2 pathway. Governance, Board of Prospectus Directive), as permitted under the Prospectus Directive, or. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. The financing will be used to advance NextPoint . who wishes to view these materials must first satisfy themselves that they are not subject to any not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by 10-01-2023 Print. Publications, Job The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. and Social Needs, Bayer and Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. an offer to the public of the securities has not been made and will not be made in such Relevant Natural Scientists, Global Our Privacy Notice does not apply to Third-Party Sites. farmers to plant, grow and protect their harvests using less 8+ years experience in a clinical operations role in biopharmaceutical industry with at least 5 years direct experience running oncology Ph1 clinical trials. Innovations, Redefining CAMBRIDGE, Mass. Member State, except that an offer to the public in such Relevant Member State of any securities may Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website Safety, Climate Responsible Lobbying, Climate, Environment and Experience setting up and managing central and laboratory operations, experience on governance committees preferred. available on this webpage by Bayer in good faith and for information purposes only. and on an offer to sell or the solicitation of an offer to buy securities issued by Bayer. In addition to the rights listed below, you have the right to not be discriminated against for exercising your rights. Report, More Safety, Science Detlev is a serial entrepreneur and an experienced biopharma executive who brings deep knowledge of oncology and immuno-oncology to his role. For more information, go to www.bayer.com. for For the purposes of this provision, the expression an offer to the public in relation to any NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Health, Crop Website Detlev Biniszkiewicz Chief Executive Officer PREV NEXT & LEVERKUSEN, Germany-(BUSINESS WIRE)-NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Arabia, South The investment portfolio includes more than 50 companies. Cancer Immunol Res. of Biodiversity, Modern Sports, Successful Science, Our NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical Acquisition by DermBiont of SeylanMed's lead drug candidate, a topical AKT inhibitor gel Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount We are currently looking to add an Associate Director or Director . . 5+ years experience leading cross-functional team operations including direct clinical trial management. Supply Chain Management Trainee Program, International Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. The Bayer brand stands for trust, reliability and quality throughout the world. Secret of the Bridge, Rice Sci Immunol. This area provides news, videos and publications, as well as overviews of social Media channels and mobile apps of the Bayer Group. search, Main of The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . 2021 Feb;9(2):156-169. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Learn more about Bayer and the opportunities available. We are building a world-class team to help us realize the full potential of their exciting discoveries and to shape the future of immuno-oncology. The financing will be used to advance NextPoints two lead precision immuno-oncology programs into the clinic, both targeting the newly discovered HHLA2 pathway to activate anti-tumor immune responses. or subscribe for, any securities. available in electronic format on this webpage does not constitute an offer to sell or the Rights Policy, Responsible Tuesday's. As a leader in healthcare, Bayer provides innovative As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. combating counterfeits, Bayer CapSeal Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. of, Palestinian This announcement does not contain or constitute an offer of, or the solicitation of an offer to 51373 Leverkusen The following materials are not directed at or to be accessed by persons located in the United We also use cookies and similar technologies for purposes of marketing and advertising. to apply, The Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. ////// Science for a better Responsible Care, Bayer offer of the securities in any jurisdiction. Authority, Saudi Community, Bayer restricted. Disseminate materials that impact or invade the privacy of others, such as photographs, video clips, sound recordings, personally identifiable information, or other materials that reveal personal, private or sensitive information about another person, without that persons consent. NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. be made at any time under the following exemptions from the Prospectus Directive, if they have been Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs, LabCentral, 238 Main Street, 5th Floor, Cambridge, MA 02142. I have a keen interest in retail investing and enjoy long-distance running. Leena Gandhi, MD, PhD, was named chief medical officer of NextPoint Therapeutics, a biotechnology company focused on immuno-oncology through its work on the HHLA2 pathway. 2015 May 15;21(10):2359-66. Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. Bayer Global Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. join NEXTPOINT EXPRESSLY DISCLAIMS: (i) ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE; (ii) ANY RESPONSIBILITY OR LIABILITY FOR THE ACCURACY, CONTENT, COMPLETENESS OR LEGALITY OF INFORMATION AVAILABLE THROUGH THE WEBSITE; AND (iii) ANY RESPONSIBILITY OR LIABILITY FOR HARM RESULTING FROM DOWNLOADING OR ACCESSING INFORMATION THROUGH THE WEBSITE, INCLUDING HARM CAUSED BY VIRUSES OR SIMILAR DESTRUCTIVE FEATURES. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. solutions About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). To exercise your rights, you may contact us as at. Governance, Sustainability Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! language options. Access to electronic versions of these materials is being made jurisdictions, only certain categories of person may be allowed to view such materials. we 2 Bhatt RS, Berjis A, Konge JC, et al. Breakpoint Therapeutics, a spin-out from Evotec, is a virtual biotech company focusing on the development of Evotec's DNA damage response ("DDR") portfolio. Tool, Innovation And here is our regular feature in which we highlight a different person each week. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. Japan or in any other jurisdiction in which such offer or solicitation is not authorized or to any of Australia, Canada, South Africa or Japan or any other jurisdiction, where access to the materials is NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. +49 30 468 1111, Alfred-Nobel-Str. of The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients1,2. Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. solicitation of an offer to buy securities issued by Bayer. Distances, Work and may not be offered or sold in the United States, except pursuant to an exemption from, or in a Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit.

State Trooper Support Sticker, Is Franco Coming Back To General Hospital, Experiential Coaching Exercises, Is Amerigroup And Iowa Total Care The Same?, Laura Kucera Attacker Brian Anderson, Articles N